Zacks Small Cap Research – CLPMF: Clip Money Reports Q3 Revenue Growth of 250% – Go Health Pro

By Lisa Thompson OTC:CLPMF READ THE FULL CLPMF RESEARCH REPORT Revenue is ramping even faster than we expected, as shown by the Q3 earnings report. Revenue for Q3 2024 was $521,000 compared to $149,000 in Q3 of 2023, representing 250% growth. In the quarter, the number of new deposit users grew by 101%, and revenue … Read more

AI-generated shows could replace lost DVD revenue, Ben Affleck says – Go Health Pro

AI-generated shows could replace lost DVD revenue, Ben Affleck says – Go Health Pro

Last week, actor and director Ben Affleck shared his views on AI’s role in filmmaking during the 2024 CNBC Delivering Alpha investor summit, arguing that AI models will transform visual effects but won’t replace creative filmmaking anytime soon. A video clip of Affleck’s opinion began circulating widely on social media not long after. “Didn’t expect … Read more

Zacks Small Cap Research – MHH: Revenue Growth Returns to Mastech Digital – Go Health Pro

By Lisa Thompson NYSE:MHH READ THE FULL MHH RESEARCH REPORT After seven quarters of declining year-over-year revenues, Mastech (NYSE:MHH) reported revenue growth of 8.5% in Q3 2024. Gross margin was again at an all-time high, and income is growing faster than revenues. As a result, we are raising our Q4 2024 and 2025 EPS estimates … Read more

Opportunities For Smart Home Service Revenue – Go Health Pro

Opportunities For Smart Home Service Revenue – Go Health Pro

A new ABI Research study reveals that smart home service revenues grew during 2022, but there is a clear disconnect between smart home adoption and the immediate value to service providers. Total smart home services revenue for 2022 reached US$32.7 billion, up 2% over 2021, well below the more than 20% growth rate in the … Read more

Zacks Small Cap Analysis – CTSO: CytoSorbents Potential for Excessive Margin Income Progress Helps Worth Goal of $4.00 – Go Well being Professional

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT CytoSorbents (NASDAQ:CTSO) reported 2nd quarter 2024 outcomes on August thirteenth and the outcomes have been principally above our expectations. For the 2nd quarter of 2024, complete revenues elevated roughly 5.0% to $9.9 million. Complete product gross sales have been $8.8 million, a rise of … Read more